1. Home
  2. GRF vs IXHL Comparison

GRF vs IXHL Comparison

Compare GRF & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

N/A

Current Price

$10.12

Market Cap

39.9M

Sector

Finance

ML Signal

N/A

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$3.35

Market Cap

37.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRF
IXHL
Founded
1989
2001
Country
United States
Australia
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
37.0M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
GRF
IXHL
Price
$10.12
$3.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.7K
255.9K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
N/A
EPS
1.16
N/A
Revenue
N/A
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.60
$0.16
52 Week High
$11.85
$6.39

Technical Indicators

Market Signals
Indicator
GRF
IXHL
Relative Strength Index (RSI) 54.14 43.89
Support Level $9.96 $2.68
Resistance Level $10.29 $3.68
Average True Range (ATR) 0.07 0.27
MACD 0.01 -0.02
Stochastic Oscillator 71.84 28.68

Price Performance

Historical Comparison
GRF
IXHL

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: